Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Patent
1997-01-31
1998-12-22
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
514561, 514553, A61K 900, A61K 31195
Patent
active
058515372
ABSTRACT:
A salve includes a water-miscible, hydrophilic cream vehicle, 1-22% by weight a-DFMO, and no absorption enhancer. The salve is preferably contained in an ointment tube permanently sealed at one end to preclude exposure to light and air. The salve is applied as a preventative in an appropriate amount twice daily to skin exposed to actinic radiation. An initial application of a salve including 10% by weight A-DFMO is preferred to minimize the risk of skin irritation without compromising the therapeutic value of the salve. The salve shows no systemic uptake, thereby eliminating systemic toxicities that result from other techniques for administering the drug.
REFERENCES:
patent: 4433051 (1984-02-01), Gilad et al.
patent: 4818770 (1989-04-01), Weinstein et al .
patent: 4859452 (1989-08-01), Ajani et al.
patent: 4988724 (1991-01-01), Ajani et al.
patent: 5013719 (1991-05-01), Bowlin
patent: 5132293 (1992-07-01), Shander
patent: 5162373 (1992-11-01), Ajani et al.
patent: 5189025 (1993-02-01), Ajani et al.
patent: 5328686 (1994-07-01), Shander
patent: 5455161 (1995-10-01), Assaraf et al.
McCullogh, et al., "Regulation of Epidermal Proliferation in Mouse Epidermis by Combination of Difluoromethyl Orinithine (DFMO) and Methylglyoxal Bis(guanylhydrazone)", 85: 516-521, 1985.
Gensler, "Prevention by .alpha.-difluoromethylornithine of skin carcinogenesis and immunosuppression induced by ultraviolet irradiation", J. Cancer Res Clin Oncol. 117: 345, 1991.
Alberts, et al., "Positive Randomized, Double Blinded, Placebo Controlled Study of Topical Difluoromethyl Orinithine (DFMO) in the Chemoprevention of Skin Cancer", Annual Meeting of the American Society of Clinical Oncology, vol. 15, May, 1996.
Takigawa et al., "Polyamine Biosynthesis and Skin Tumor Promotion: Inhibition of 12-0 Tetradecanoylphorbol-13-Acetate-Promoted Mouse Skin Tumor Formation by the Irreversible Inhibitor of Ornithine Decaboxylase .alpha.-Difluoromethylornithine", vol. 105, No. 3, p. 969, Apr. 14, 1982.
Meyskens, et al., "Phase II study of .alpha.-difluoromethylornithine (DFMO) for the treatment of metastatic lanoma", 4:257, 1986.
Weeks, et al., ".alpha.-Diluoromethylornithine, an irreversable inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin", 79: 6028, Oct. 1982.
Grosshans, et al., "Les Polyamines Dans Le Psoriasis", 107:377, 1980.
Kishue J. of Nutritian, Growth & Cancer (1985) vol. 2 p. 91-99.
Takigawa Cancer Res. 43, 3732, 1983.
Kapyaho J. Invest. Dermatology 81, #2, p. 102, 1983.
Alberts David S.
Dorr Robert T.
Cancer Technologies, Inc.
Kishore Gollamudi S.
LandOfFree
Topical application of .alpha.-DFMO for preventing skin cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical application of .alpha.-DFMO for preventing skin cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical application of .alpha.-DFMO for preventing skin cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2043372